Drug Combination Details
| General Information of the Combination (ID: C80165) | |||||
|---|---|---|---|---|---|
| Name | Bufalin NP Info | + | Vorinostat Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2016 Sep 9;478(1):227-233. | |||
